ED50 (Effective Dose 50) refers to the dose of a drug or substance that produces a desired effect in 50% of a population or sample under a given set of experimental conditions or in a group of test subjects.

The European Commission has granted UCB approval for BIMZELX®(bimekizumab), marking it as the initial biologic targeting both IL-17A and IL-17F for treating moderate to severe hidradenitis suppurativa.

The challenge is finding how to effectively alleviate these symptoms while maintaining sufficient safety. Tavapadon has found a balance in addressing this issue.

U.S. FDA Sanctions Takeda’s ENTYVIO® (vedolizumab) for Subcutaneous Use in Managing Moderate to Severe Crohn’s Disease.

Radioactive therapeutic drugs, also known as radioactive drugs, mainly function based on the particles or rays produced by the radioactive decay of radionuclides.

Chugai Secures Licensing Deal with Roche for Hypertension Drug Zilebesiran in Japan.

April 24th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Cerevel Therapeutics Reveals Encouraging Initial Outcomes from Phase 3 Supplementary Study of Tavapadon in Parkinson’s Disease Patients.

The storage method for radioactive drugs needs to follow specific safety and protection standards to ensure the safety and effectiveness of radioactive substances.

D2M Biotherapeutics has initiated a Phase 1 trial by administering the first dose of DM919, an innovative MICA/B antibody, aimed at treating individuals with advanced solid tumors.

On April 22, 2024, ImmunityBio's Anktiva (N-803) plus BCG got FDA approval for BCG-unresponsive NMIBC with CIS, with/without papillary tumors.

Pathios Therapeutics Secures $25M in Initial Series B Funding Round to Propel Unique Immunotherapy Strategy into Clinical Trials.